Peregrine Pharmaceuticals, Inc. (PPHM), Tustin CA. http://www.peregrineinc.com
Avid Bioservices, Inc. (wholly-owned mfg. subsidiary): http://www.avidbio.com
Yahoo Quote & Profile for PPHM: finance.yahoo.com/q
IR: BioCom Partners, NYC 800-987-8256 http://www.biocompartners.com - info@peregrineinc.com
Media: Barbara Lindheim, BioCom Partners, NYC 212-918-4650
Dr. Philip Thorpe’s lab at UTSW/Dallas, Peregrine, NIH-NIAID/CHAVI, Gates/CAVD, DOD/DTRA/TMTI, Affitech, SFBR, Health Protection Agency(UK) and UCLA/Harvard/Tulane/NYU/UC-Irvine/UtahST/UT-Galveston/Missouri Univ's take dead aim on ALL ENVELOPED VIRUSES (VHF, HIV, Influenza/Avian Flu, HepC, CMV, RSV…) and ALL SOLID TUMOR TYPES with Anti-Phospholipid Therapy (APT) agents, like Anti-PS/3G4/Bavituximab(formerly Tarvacin), which are “surprisingly effective in inhibiting the entry, replication and spread of viral infections”, and are ”suitable for treating all forms of cancer", including patients that "have, or are at risk for developing, vascularized solid tumors, metastatic tumors, or metastases from primary tumors”. Bavituximab is categorized as an 'anti-phosphotidylserine immunotherapeutic', which attempts to stimulate or activate the immune system to reject and destroy tumors or to respond to infectious agents.
VIDEO: “Understanding Bavituximab” (added 10-2006): http://tinyurl.com/yjsb5w (Thorpe thruout, Lee Rosen @3:40+4:50, Melina Soares @6:50)
4-24-2006: Tarvacin (chimeric mab 3G4) will henceforth be referred to by its generic name, BAVITUXIMAB, to avoid confusion with OSI’s anti-cancer drug Tarceva. http://tinyurl.com/2vawjv
Bavituximab's Anti-Viral MOA: http://tinyurl.com/2s2syx Clinical Trials Overview: http://tinyurl.com/37xotu
Bavituximab's Anti-Cancer MOA: http://tinyurl.com/3xb348 Clinical Trials Overview: http://tinyurl.com/2rjedz
PEREGRINE'S SRB - LINKS TO PROFILES & PUBMEDS: http://tinyurl.com/2cy3cv
EXPERT QUOTES/COMMENTARY ON BAVITUXIMAB's MOA/POTENTIAL: http://tinyurl.com/nmdw4
FACT SHEETS (PDF's) on Peregrine, BaviAC, BaviAV, Cotara: http://tinyurl.com/3yldda
'Anti-PS Anti-Viral Tech. Backgrounder' (PDF), added 1-6-09: http://tinyurl.com/nvmt3b
'Anti-PS Anti-Cancer Tech. Backgrounder' (PDF), added 5-7-09: http://tinyurl.com/ppurlx
JBM’s interesting & educational blog on Anti-PS science, esp. HIV: anti-ps.blogspot.com
Ken Goodrich’s StockSeasonality iHub board & website: tinyurl.com/puxdyn & www.stockseasonality.com
Latest 10K 4-30-09 iss. 7-14-09: http://tinyurl.com/nvk7xo PR: http://tinyurl.com/nt4zql (cash 4-30-09 $10.0mm)
Latest 10Q 10-31-09 iss. 12-10-09: http://tinyurl.com/y8r7swr PR: http://tinyurl.com/ykyp5xe (cash 10-31-09 $13.6mm)
ALL SEC filings for PPHM: http://tinyurl.com/6d4jw8
Shares O/S as of 10-31-09: 48,869,563 - history since 2007: http://tinyurl.com/yb8juq3
INSIDER-Trans: http://tinyurl.com/ypkow8 & http://tinyurl.com/2yvlj4
Inst. Holdings (Nasdaq.com) - updated qtly, 45-days after each q/e cutoff: http://tinyurl.com/ys7fed
Short Interest, upd. twice a month: http://tinyurl.com/552p6n ...Updates 1 day earlier: http://tinyurl.com/292xyd
NASDAQ Last Sale (NLS) & Official Close for TODAY: http://tinyurl.com/kvplmj ...DETAIL: http://tinyurl.com/oc58jw
PPHM's 31 days with Vol. > 10mm shares (since 1996): http://tinyurl.com/nplgc6
Shareholder Rights (‘Poison Pill’) adopted 3-16-06: http://tinyurl.com/yvypvh - 44-pg SEC filing: http://tinyurl.com/5m57ut
PPHM’s Corp. Bylaws (a/o 12-21-07): http://www.secinfo.com/dV3p8.u4av.d.htm
Peregrine’s Patent Estate – excl. licenses from UTSW MDA U-CALIF USC: http://tinyurl.com/58cn74
AVID BIOSERVICES, Inc. (Peregrine's Mfg. Subsidiary): http://www.avidbio.com
...Avid Rev's Table (last 4 qtrs, thru 10-31-09: 5.8+5.0+2.1+5.3=$18.2mm): http://tinyurl.com/ycby4y4
12-3-09 AVID+PPHM JOBS: Apr-Nov’09: 20 filled + 15 curr. openings http://tinyurl.com/y9w8oae
11-20-09: ‘BIOSIMILARS’ – New Thrust for Avid? (Richieri & Garnick) http://tinyurl.com/ya5x2z8
4 articles in 2009 ref. Avid (Disposables, Biosimilars, Economy, Revs): http://tinyurl.com/yz9mcht
9-21-09: Avid becomes sole U.S. W.Coast CMO in Boehringer Ingelheim's Global Prod. Alliance Network http://tinyurl.com/l9nf4n
8-28-09: Avid adds Truc Le as COO & Chris Eso as VP/Bus.Oper. http://tinyurl.com/m85erv
5-13-09: VP Rich Richieri presents Avid’s tech. at BIO-INTL'09 http://tinyurl.com/oe3lsm PDF: http://tinyurl.com/yk78fk5
11-10-08: Avid expands capacity by adding 100L & 1000L Hyclone bioreactors: http://tinyurl.com/69qgl5
10-27-08: Avid Becomes CMO for Catalyst Biosciences’ protease candidate CB813: http://tinyurl.com/5fg7zg
6-25-08: Avid Selected as 1st U.S. CMO for DSM/Crucell’s PER.C6 Cell Line: http://tinyurl.com/4geqxw
…9-30-08 Crucell gets $40mm NIAID/BARDA award for Ebola-Marburg Vaccine: http://tinyurl.com/4wc2of
8-7-09: Avid & Cook remain Halozyme's 2 CMO's: http://tinyurl.com/lpuokl
7-14-08: Avid is CMO for Arius Research’s lead drug, “AR001 Targeting CD44”: http://tinyurl.com/6hrwrt
...7-23-08 Roche buys Arius for $190mm : http://tinyurl.com/5fg6jd
AFFITECH-PPHM Collab: Fully-Human Mabs, Anti-PS & Anti-VEGF/2C3 http://tinyurl.com/bxyfjk
• AT001 is clearly Fully-Human 2C3 = R84 = PGN311.
• AT004 & AT005 appear to be Fully-Human BAVI= PGN635=1N11, and the Duke-PPHM-HIV candidate PGN632=11.31. It’s unclear which is which.
...7-22-09: Peregrine Licenses Anti-VEGF mabs (incl. R84) to Affitech: http://tinyurl.com/n67v57
...4-28-09 Affitech comments on PGN635 & PGN632 presented at AACR'09 http://tinyurl.com/cxkcb4
UPCOMING EVENTS:
Q1-CY'10: The long-awaited Duke-PPHM Haynes/Moody HIV Article in Nature-Medicine: http://tinyurl.com/yj82gvd
…Dr Haynes 5-1-09, “The (CHAVI) B Cell Discovery Team has defined a class of anti-lipid antibodies with breadth of protection in vitro PBMC assay for R5 transmitted/founder strains. (Nature Medicine, submitted 2009)”. KEEP CHECKING: http://www.nature.com/nm & click "AOP".
Feb9 3:30-3:55pm *WEBCAST*: 12th Annual BIO CEO & Investor Conf./NYC http://tinyurl.com/y9jrdv5
…“The world's largest gathering of the biotech industry, along with industry-leading innovator & partnering meetings held around the world.”
Mar3-5, Dr. Rob Garnick, keynote pres. (1 of 4) at IBC Antibody Conf., Carlsbad http://tinyurl.com/ybtvkc4
. . .Dr. Garnick: “Global Regulatory Strategies for Validation & Transfer of Biotech Processes & Products”
Mar11: Gordon Research Conf., “Antibody-Based Therapeutics”, Ventura CA http://tinyurl.com/yeux6r6
…8:25-9:05pm: Dr. Philip Thorpe joins discussion leader Andrew Chan (SVP, Immunology, Genentech) in the “Therapeutic Antibodies” session, speaks on "Targeting PS in the Tumor Microenvironment to Destroy Tumor Blood Vessels & Induce Tumor Immunity"
Mar25 2-3pm: Philip Thorpe, Notre Dame Univ. CBBI Seminar (NIH-funded) http://cbbi.nd.edu
Apr17-21: “AACR 101st Annual Meeting 2010”, WashDC http://tinyurl.com/ya663ce
May4-6/Avid: “2010 BIO Intl. Convention”, Chicago http://convention.bio.org
May16-18: “Rodman&Renshaw 6th Annual Global Healthcare Conf.”, London http://tinyurl.com/yejnmwq
Jun4-8: “ASCO Annual Meeting 2010”, Chicago http://www.asco.org/AnnualMeeting
BAVITUXIMAB SOLID CANCERS PHASE 1+2 TRIALS:
==> PR=Partial-Resp(30-99% Red.), SD=Stable-Disease(29% Red.-19% Incr.), OR=Obj-Resp(PR+CR)
1-14-10: Peregrine’s Ambitious Goal for Bavi: Accelerated Approval after Phase II: http://tinyurl.com/y9gsf9x
1-12-10: #WEEKS Calcs. & Early Comp. vs. Avastin for the 3 Bavi+Chemo Ph.2 trials: http://tinyurl.com/ykd7a7k
10-6-09: EST. of Total #Patients treated with Bavi to date (Cancer & Viral): 252. http://tinyurl.com/yclyfyt
6-3-09: Peregrine highlights progress in all 3 Ph.2 Bavi Trials: http://tinyurl.com/pe923n
…CEO S.King, “Having just completed a busy round of successful data presentations & partnering meetings at ASCO’09, we are gratified at the level of interest the Bavi pgm is now receiving from leading cancer researchers & drug developers."
E. Phase II Bavi+CP vs. Adv./Met. Breast Cancer in INDIA:
India’s DCGI protocol (init=8-2008): http://clinicaltrials.gov/ct2/show/NCT00669565
…Early ORR% comp. vs. SOC: Bavi+CP/60% n=15, Avastin+PAC/37% Ph.2/ABC n=347
9-8-09: Stage2 enrollment complete (15+31=46 total). http://tinyurl.com/mynmb8
4-27-09: After full 24wk combo regimen, 9 of 15 (60%) achieving OR http://tinyurl.com/c9hna4
…Also, Dosing Underway in Stage2 (addl. 31 patients).
3-12-09 CC, J.Shan: since the 2-11-09 PR, “we have seen addl. tumor responses.” http://tinyurl.com/cwyo6f
2-11-09: At 8wks (of 24wk combo regimen), 7 of 14 (50%) achieving OR, incl. one C.R. http://tinyurl.com/aquf8r
10-7-08: 1st-15 enrolled http://tinyurl.com/47kvj8 , 8-11-08: 1st-dosed http://tinyurl.com/5ogfxa
1-23-08: Ph.2 protocol approved by DCGI, “looking fwd to study initiation in the near future.” http://tinyurl.com/2rks5y
9-10-07: Protocol Submitted to Indian Drug Controller General: http://tinyurl.com/yqm8e7
…”15 patients with MBC initially; exp. to 46 if promising results are observed in the 1st cohort; primary obj: assess overall response.”
D. Phase II Bavi+CP Adv./Met. Lung Cancer (NSCLC) in INDIA:
India’s DCGI protocol (init=6-2008): http://clinicaltrials.gov/ct2/show/NCT00687817
…Early Ph.2/Adv.Lung ORR% comp. of Bavi+CP/52% n=21 vs. Avastin+CP/32% n=35.
10-5-09: S2(28pts) enrollment complete; MedianPFS=6.5mos in Stage1/n=21 http://tinyurl.com/y9wnh5p
6-3-09: Ph.2 highlights: 11 of 21 [52.4%] of Stage1's acheived OR: http://tinyurl.com/pe923n
4-20-09: Prelim. data, 17 evaluables at 18wks (6 of 6 cycles): 8 OR’s = 47% ORR http://tinyurl.com/cwytaf
…Also, Dosing Underway in Stage2 (addl. 28 patients).
2-4-09: Prelim. data, 17 evaluables at 12wks (4 of 6 cycles): 6 PR’s + one C.R. = 41% ORR http://tinyurl.com/dlotdx
10-20-08: 1st-21 enrolled http://tinyurl.com/5wnhog , 6-30-08: 1st-dosed http://tinyurl.com/69aut8
1-22-08: Ph.2 protocol approved by DCGI, “looking fwd to study initiation in the near future.” http://tinyurl.com/2t6k7j
7-11-07: Protocol Submitted to Indian Drug Controller General: http://tinyurl.com/yoxpjl
…"21 patients with Adv. NSCLC initially; exp. to 49 if 1st cohort results positive; primary obj: assess overall response."
C. Phase II Bavi+Docetaxel vs. Adv./Met. Breast Cancer in E.EUR.(Georgia):
Georgia Ministry of Health protocol (init=1-2008): http://clinicaltrials.gov/ct2/show/NCT00669591
…Early Ph.2/MBC ORR% comp. of Bavi+Doce/61% n=46 vs. Avastin+Doce/52% n=27.
10-21-09: Update on ALL S1+S2, 28 of 46 (61%) acheived Obj. Tumor Resp. http://tinyurl.com/yjlu4yc
6-1-09: ASCO’09 oral presentation (StageA/15pts: 67% ORR & 7.4mos.PFS): http://tinyurl.com/pbf9gw
5-4-09: Stage2 enrollment complete (15+31=46 total): http://tinyurl.com/cp737p
10-21-08: “10 of 15 (67%) Stage1's achieved an objective tumor response.” http://tinyurl.com/6qx4gp
…Mojo’s early comp of Bavi+Doce Ph.2 vs. Avastin+Chemo trials - PFS% chart: http://tinyurl.com/5rergk
9-9-08 SK: “We 've now seen addl. patients with tumor responses, with 9 of the 14 evaluables (64%) having achieved PR.” http://tinyurl.com/5q9phf
7-2-08: Ph.2 Bavi+Doce/Breast update. http://tinyurl.com/5tvfhy
…”At 8wks (of 24wk combo regimen), 100% of [1st 14] evaluables showing OR/SD; 7 of 14 (50%) achieving PR”
6-2-08: ASCO/2008 Ph.2 Bavi+Doce/Breast Update: http://tinyurl.com/5xll6f
…”At 8wks (of 24wk combo regimen), 100% of [1st 11] evaluables showing OR/SD; 5 of 11 (45%) achieving PR”
4-29-08: 1st-15 enrolled http://tinyurl.com/47o85x , 2-12-08: 1st-dosed http://tinyurl.com/36c28s , 1-29-08 Enroll. begins http://tinyurl.com/22ecb2
11-16-07: Ph.2 protocol approved. “Patient Enrollment expected by early 2008.” http://tinyurl.com/3aavzh
10-22-07: Protocol Submitted to Ministry of Health, Rep. of Georgia: http://tinyurl.com/2xjjgp
…”15 patients with MBC initially; exp. to 46 if promising results are observed in the 1st cohort; primary obj: assess overall response.”
B. Phase 1B Combo-Therapy Trial in INDIA: (init=11-2006 comp=5-2007)
###10-10-07: MRI's of 2 India/1B Met.Breast Cancer patients, B4 & 8Wk-mark after Bavi+CP: http://tinyurl.com/2xt7r8
6-2-08: ASCO, Dr. Raghunadharao Digumarti (PI, Nizams Inst., India) presents Ph.1B data: http://tinyurl.com/5xll6f
…Dr. Digumarti, "Bavi represents a completely novel approach to treating cancer that helps mobilize the body's own immune system to attack tumors & the blood vessels supporting tumor growth & spread. We believe these encouraging study results support the upcoming Ph.2 safety/efficacy trials of Bavi in breast & lung cancers that we look fwd. to participating in."
5-31-07: Top-Line Data for 12 Evaluable Indian patients http://tinyurl.com/2rzeen
…”ALL12: 50%=OR/SD… Bavi+GEM: 75%=OR/SD… Bavi+CP: 50%=OR” - in ”adv. cancer patients with metastatic disease who had failed prior therapy.”
11-17-06: Dosing Underway in India Ph.1B Combo Trial http://tinyurl.com/tg46h
...”Up to 12 patients will rec. bavi along with Docetaxel, Gemcitabine, or Carboplatin/Paclitaxel for 8wks, at 3 sites in India, with 4wk followup."
###BP Possibilities for 2008 Ph.II Bavi+Chemo AC Trials: http://tinyurl.com/2ecnuv
A. Phase 1A Monotherapy Trial in USA - Advanced Solid Cancers:
Trial protocol (init. 6-2005): http://clinicaltrials.gov/ct/show/NCT00129337
...Per Nov’08 MDA 'Extension-Protocol', appears at least 1 OTR as of Mar'09: http://tinyurl.com/dgpyvx
6-30-09: Enrollment complete: http://tinyurl.com/kpxs23
6-1-09 ASCO’09: Ph.1 Bavi-Mono/Solid-Tumors/USA, poster: http://tinyurl.com/p7jku7
6-10-09: ASCO $200k Grant to UTSW's David Gerber for New Bavi/NSCLC Study: http://tinyurl.com/nt4na9
6-10-05: Ph.1A trial initiated at Arizona CC: http://tinyurl.com/96wdf - "up to 28 patients with adv. solid tumors that no longer respond to std. cancer treatments. Patients who demonstrate an obj.resp. may be offered continued treatment on an ext. protocol."
BAVITUXIMAB HEP-C PHASE1 TRIALS:
C. Phase 1B HCV-HIV Co-Infected’s Mono Repeat-Dose Trial:
NIH protocol (init=7-2007): http://clinicaltrials.gov/ct/show/NCT00503347
7-10-07: Enrollment begins at St.Michaels (Peter Ho Mem. Clinic, NJ) http://tinyurl.com/2g7rdp
...Ascending dose levels of Bavi weekly for 8 wks; ~24 pts; designed to assess Safety & PK, but “HCV & HIV viral titers & other biomarkers will be evaluated”.
5-17-07: New Clinical Protocol filed with FDA: http://tinyurl.com/2lpacm
B. Phase 1B HCV Monotherapy Repeat-Dose Trial:
NIH protocol (init=6-2006 comp=1-2007): http://clinicaltrials.gov/ct/show/NCT00343525
11-5-07: Dr. Lawitz, Ph.1B data at AASLD’07 (Mono/Repeat-Dose, 24pts): http://tinyurl.com/3chefc
…Dr. Lawitz: “Bavi has a novel targeted immunomodulatory moa and if proven effective, it has the potential to be complementary to emerging new AV therapies for HCV infection."
6-7-06: ”Dosing Has Begun In A New Ph. Ib Repeat Dose Study” http://tinyurl.com/rs6ej
A. Phase 1A HCV Monotherapy Single-Dose Trial (Non-Responders):
NIH protocol (init=8-2005 comp=2-2006): http://clinicaltrials.gov/ct/show/NCT00128271
10-30-06: Dr. Godofsky, Ph.1A data at AASLD'06 (Mono/Single-Dose, 30pts) - Godofsky http://tinyurl.com/ypklfm
Dr.Godofsky, "Bavi has a unique proposed immunotherapeutic moa with the potential to complement existing & investigational therapies for this common viral infection with few curr. treatment options."
COMPANY UPDATES & ARTICLES: [ PPHM News: http://finance.yahoo.com/q/h?s=PPHM ]
1-13-10: CEO Steve King’s 16min. talk at OneMedForum2010 (SanFran) http://tinyurl.com/yb7v2u4
…”The [next] study we have discussed with the FDA is Bavi+Doce in 2nd-line NSCLC. In this patient population, they have about a 6% resp. rate; so, a high unmet medical need, and we think an excellent opportunity for development. The trial design we’ve agreed to with the FDA is essentially a registrational Ph.2 design; it’s going to be about a 120 patient study, double-blinded, placebo-controlled… the goal being, if we see positive results & excellent results, that we really want to be able to take advantage of that and potentially approach the agency about Accelerated Approval.”
1-11-10: Dr. Marvin Garovoy (Ex-XOMA VP) joins PPHM as Head/Clin.Science http://tinyurl.com/yz4fwyv
…Dr. Garovoy will have primary responsibility for establishing & supervising an Investigator-Sponsored Trials (IST) pgm, as well as expanding scientific outreach & assisting with clinical trial design for the Bavi & Cotara pgms.
…CEO SK: ”These ISTs can be a very important part of our overall clinical dev. pgm, potentially providing invaluable info. that might not otherwise be obtained from our company-initiated trials.”
…Dr. Garovoy, “Bavituximab is a promising new approach with broad potential for the treatment of solid cancers and other diseases. Based on the encouraging results seen in early clinical trials, I welcome the opportunity to collaborate with clinical researchers to establish the investigator-sponsored studies that will enhance our understanding of the clinical potential of this exciting new agent."
12-10-09 Qtly. Conf. Call (King/Lytle/Eso/Garnick) Transcript http://tinyurl.com/yakx4mp
Dr. Robert Garnick (Head/Regulatory), “After carefully studying the company’s PS-Targeting Antibody platform and its lead product candidate bavituximab, I became extremely excited and agreed to work with Steve and his team to help guide the drug’s development, focusing specifically on how we might accelerate its progress towards marketing approval. I’d like to say that bavituximab reminds me a great deal of a similar and very important monoclonal antibody, Rituxan, because of the biological elegance of its moa. Because of the similarity, the regulatory approach I’m recommending to Peregrine for bavituximab is very consistent with the approach we took at Genentech for obtaining the approval of Rituxan. I’m extremely optimistic that bavituximab may represent a unique & valuable new approach to the treatment of advanced refractory cancer in combination with chemotherapy or radiation, and based on its moa may potentially be useful in anti-viral and other indications as well. In addition to my personal scientific interest in the potential Peregrine’s technology, I’ve also been very impressed with the Peregrine team and the mix of professionalism, enthusiasm, and commitment that are so reminiscent of my early days of Genentech. …Our goal is to implement a clinical & regulatory strategy that will maximize our chances of getting bavituximab approved and to do so in the shortest feasible timeframe.”
10-19-09: Dr. Robert Garnick (former DNA Exec) appointed Head/Reg.Affairs http://tinyurl.com/yga7z4x
...examples of Dr. Garnick's work at Genentech on Avastin (bevacizumab) approvals: http://tinyurl.com/yg7vtqa
...All of Dr. Garnick's comments (thru 12/2009) re: his new assoc. with PPHM: http://tinyurl.com/yjd3ucc
11-3-09: PPHM Regains Full Nasdaq Compliance: http://tinyurl.com/yzesqdg
...10-16-09/PPHM to Execute 1:5 R/S on 10-19-09: http://tinyurl.com/ykuw588
...7-25-07/Init. Nasdaq Def. notice: http://tinyurl.com/2suakw , 7-14-09/Final ext. till 11-11-09: http://tinyurl.com/nvk7xo
10-5-09: PPHM Snapshot in OC-Register, by Vita Reed: http://tinyurl.com/y8qp23f
…”Tustin-based Peregrine reached #1 on the Bus.Journal’s 2009 list of fastest-growing public companies based here by posting a 380.4% rev. growth rate for the 3-yrs. ended 6-30-09… Peregrine’s [DTRA] work on bavituximab for VHF could lead to another contract to make the drug, according to King.”
9-10-09 CEO S.King’s R&R Healthcare Conf./NYC, webcast replay: http://tinyurl.com/y9vutws
...See Slides: 42=Upcoming Milestones, 31=AntiPS-Collab's, 08=“Increasing Recognition of PS Importance”
9-3-09 Qtly. Conf. Call (King/Lytle/Eso/Shan) Transcript http://tinyurl.com/nuykr2
...SK, "The results we’ve seen to date from both the Bavi & Cotara Ph.2 trials have already convinced us to begin planning the next series of clinical trials."
7-30-09: CEO Steve King interview video, by J&L’s Bill Dawson for OneMedPlace: http://tinyurl.com/lqwedd
7-14-09 Qtly. Conf. Call (King/Lytle/Shan) Transcript http://tinyurl.com/nt4zql
...SK, “with potential partnering activities well underway… we believe our company’s future has never looked brighter.”
3-27-09: Forms 8-K/424, ‘At Market Issuance Sales Agreement’ with Wm Smith & Co. for up to $7.5mm in gross proceeds http://tinyurl.com/c73btg
3-18-09: CFO Paul Lytle presents at the Cowen Healthcare Conf., Boston: http://tinyurl.com/cal9br
3-12-09 Qtly. Conf. Call (King/Lytle/Shan) Transcript http://tinyurl.com/cwyo6f
...SK on Bavi Cancer Trials: “One of the things we want to do is take a look at where we can differentiate ourselves, and not just from Avastin – they’re obviously highly successful, and we certainly aspire to be as successful as they have been…”
12-11-08: Peregrine Mourns Loss of Dr. Thomas A. Waltz http://tinyurl.com/6bcykt & http://tinyurl.com/64hc4k
12-10-08 Qtly. Conf. Call (King/Lytle): Transcript http://tinyurl.com/9h9696
...SK: “we anticipate the potential for a number of high profile publications coming out of this [Duke/NIH-Gates collab. Anti-PS] research.”
12-10-08: Loan Agreement for up to $10mm ($5mm Initially) http://tinyurl.com/55xl4c
11-11-08 CEO S.King, 10th R&R Healthcare Conf/NYC: http://tinyurl.com/5ahzwy
10-30-08: CEO S.King, BIO-INV. Forum (SanFran) - Replay w/slides: http://tinyurl.com/664mgd
...SK on Duke/Gates/NIH HIV collab: “At AIDS-VACCINE’08, a key finding was that certain classes of Anti-Phospholipid antibodies broadly neutralize HIV infection. And, in fact, the most potent antibodies were those that were provided by Peregrine. This is a very important finding…”
9-9-08 Qtly. Conf. Call (King/Lytle): Transcript http://tinyurl.com/3p3s33
...SK: "I'm happy to report that [Anti-PS] data from the [Duke HIV] collab. will be highlighted this fall at the prestigious AIDS-VACCINE’08 Conf. Oct13-16 in CapeTown [Haynes/Moody Oct14]. This will mark the first time that data from our collab. has been presented and we are very pleased with the opportunity to share the info. with the broader scientific community.”
7-14-08 Qtly. Conf. Call (King/Lytle): Transcript http://tinyurl.com/6jnovb
...SK: ”we have also continued our pre-clinical collab’s with Duke and other institutions evolved in evaluating our Anti-PS platform for use in the possible prevention & treatment of HIV infections. While we had hoped to have data related to the collaboration publicly available by now, the delay has been caused by an expansion of the collaboration and the generation of addl. data that only makes the story potentially more interesting. There are currently more than 40 scientists & 9 institutions involved in the collaboration.”
3-11-08 Qtly. Conf. Call (King/Lytle/Shan): Transcript http://tinyurl.com/3zj74d
...SK: “Our research collabs [with DUKE, UTSW, and others] have expanded and are extremely active. We look fwd to presenting data thru peer-reviewed journal articles in the near future that highlight the potential of our Anti-PS technology… A real positive for these preclinical pgms is that they have significant support from outside grants... ‘potentially very exciting developments we have upcoming’…”
ARTICLES, ANNUAL SHM’S, & CC’S - Archive 2005-2007: http://tinyurl.com/yanupve
BAVITUXIMAB ANTI-VIRAL NEWS:
11-4-09: 2nd Patent (7,611,704) Granted for AntiPS Broad AV apps http://tinyurl.com/y9jmsod
...”noteworthy since it includes methods for treating all viruses in humans & animals.”
10-7-09: PPHM forms ‘Anti-Viral Research Group’ http://tinyurl.com/yan3fws
…"Peregrine's broad-spectrum PS-targeting antibodies are being assessed in anti-infective applications by more than a dozen leading research institutions… Peregrine and its collaborators have already secured over $60 million in research funding to evaluate the potential of the company's PS-targeting platform in a wide range of viral infections…”
9-10-09: PPHM’s 7 Anti-PS Collaborators (S.King, R&R Healthcare Conf/NYC) http://tinyurl.com/nn4w8t
8-26-09: $763k NIAID Grant to Dr. Thorpe to Expand Anti-PS/VHF Studies: http://tinyurl.com/lxtuo3
…“The objective of the newly funded research is to evaluate a panel of new fully human anti-PS antibodies with different binding & functional properties as potential 2nd-gen. treatments.”
8-5-09: ‘New Scientist’ Article Highlights Peregrine/Thorpe/BaviAV http://tinyurl.com/mp2aku
...Dr. Thorpe, "We were doing something that was quite extraordinary. We had let the animals progress in their disease until they were heavily symptomatic, and then started treatment. It was a major accomplishment to knock that disease back."
3-31-09: 3rd (Conjugated) Anti-PE Patent (#7,511,124) Granted: http://tinyurl.com/dmkw6y
1-6-09: New ‘Anti-PS Anti-viral Factsheet’ on the PPHM Website: http://tinyurl.com/759qyw
11-24-08: Dr.Thorpe publishes in Dec.2008 NATURE Medicine on BaviAV vs. Lassa/CMV: http://tinyurl.com/9ktvsb
...Dr. Thorpe, "This is a whole new strategy for making antiviral drugs." . . . CEO S.King, "We think it has tremendous potential."
...Dr. B.Haynes, "Targeting a host cell lipid such as PS as an anti-viral strategy is an intriguing concept that may have relevance for new therapeutic and possibly prophylactic innovations in a number of virus infections."
...7-11-09 Dr. Thorpe Interview on Bavi-AV in BMED Report: http://tinyurl.com/ltudso
7-1-08: PPHM Awarded 5-yr $44mm DTRA/TMTI Contract for Anti-PS vs. Hemorrhagic Fevers http://tinyurl.com/5dxpup
…DTRA funds: $5mm immediate; $22.3mm for 1st 24-mos; can extend to $44.4mm over 5-yrs.
...10-2009: U-Pitt report for DARPA on Biologics Demand ref’s Bavi http://tinyurl.com/yaefb4j
......“Demand for ‘Broad Spectrum Viral Inhibitors’ is modeled on products like Bavituximab under dev. by Peregrine Pharm.”
...11-18-09: PPHM Presents AntiPS/VHFs pre-clin. data at DTRA/TMTI Conf. http://tinyurl.com/ycrrwub
...7-3-08 BioWorld Today article on PPHM’s DTRA Deal: http://tinyurl.com/5kr6xk
...7-23-07: DTRA Negotiations Begin: http://tinyurl.com/2t42rq ...12-18-07: Budget Cuts Halt: http://tinyurl.com/256ord
...2003-2008 Gov't Grants & Testing Collab's for Bavi-vs-VHF that led to $44mm DTRA deal: http://tinyurl.com/c53v2x
...Peregrine's $44mm award hits the DTRA website on 7-25-08 - how it ranks with others: http://tinyurl.com/6l9cec
6-16-08: Anti-PE Patents 7378386+7384909 Granted (AV): http://tinyurl.com/5p7xrk Background: http://tinyurl.com/5svmq4
5-13-08: 3 Indep. ‘SCIENCE’ pubs highlight Role of PS in Viral Infectivity: http://tinyurl.com/5zpdte
4-9-08: Dr.Thorpe presents the PE-binding peptides 'DLB' (duramycin+biotin conjugate) at AAI2008: http://tinyurl.com/6q93wk
BAVITUXIMAB ANTI-VIRAL NEWS - Archive 2005-2007: http://tinyurl.com/yanupve
- - - - - - - - - - - -
THE DUKE/HAYNES/CAVD/GATES/NIH HIV COLLABORATION:
Duke's B.Haynes DHVI website & CAVD-Reports outline Thorpe’s Role in the CAVD-Gates HIV-Vaccine Initiative:
. . . . . http://tinyurl.com/674936 and http://tinyurl.com/5xwjk4 . . .
…”Philip Thorpe is determining the role of lipid binding of anti-HIV antibodies and anti-phosphatidylserine (PS) autoantibodies to protection from HIV infection.”
…2005-July2009: All Peregrine Public Statements on the Duke HIV Collab: http://tinyurl.com/m4aggy
…10-2008: Short profiles of ~40 Gates/NIH HIV collaborators: http://tinyurl.com/57tanp
...12-18-09: Dr Haynes CHAVI update (Nov'09): http://tinyurl.com/ykbl2vs
…”We’ve worked with Peregrine for mab production of 11.31(PGN632), 11.17(new?), 1N11(PGN635=FH-Bavi), and Bavituximab for use in NHP passive immunization trials.”
...5-2009: Duke’s Tony Moody is CHAVI’s 'Chief Medical Officer' tinyurl.com/m3g9cu
...5-1-09: CHAVI update by Barton Haynes says paper on anti-Lipid antibodies "submitted to Nature Med. 2009" http://tinyurl.com/d2ucmw
…..Haynes: “B Cell Discovery Team has defined a class of anti-lipid antibodies with breadth of protection in vitro PBMC assay for R5 transmitted/founder strains.”
...3-18-09: CFO Paul Lytle on the Duke-HIV Collab. at the Cowen Healthcare Conf: http://tinyurl.com/cal9br
...“We are expecting a high-profile pub., which is currently in process thru Duke Univ., to be presented within the 1st half of 2009.”
...3-17-09 CAVD 2006-2008 Recap Report – (57-pg PDF): http://tinyurl.com/d2jpm9
...“researchers in the Haynes VDC have discovered that anti-lipid antibodies in fact may play a role in HIV-1 protection. They found that anti-lipid antibodies produced in autoimmune disease have the capacity to broadly inhibit the infection of peripheral blood mononuclear cells by virtually all CCR5-dependent HIV-1 primary isolates. They are working now to translate this finding into a novel strategy of HIV-1 vaccine development.”
...10-30-08: CEO S.KING, BIO-INV. Forum (SanFran) - replay w/slides: http://tinyurl.com/664mgd ...SK on Duke/Gates/NIH HIV collab: “At AIDS-VACCINE’08, a key finding was that certain classes of Anti-Phospholipid antibodies broadly neutralize HIV infection. And, in fact, the most potent antibodies were those that were provided by Peregrine. This is a very important finding…”
...10-14-08: “The AIDS Vaccine 2008 Conference”, CapeTown, So.Africa http://tinyurl.com/7dnmpe
......Duke’s B.Haynes & T.Moody present Anti-PS data for 1st time publicly: “The most potent mAb, PGN632 [11.31], inhibited 7/7 B & C clade HIV-1 isolates & SHIV SP162P3... Studies showed the mAbs acted at host cell surfaces to inhibit HIV-1 infection."
…..Dr. Ralph Pantophlet’s summary of T.Moody’s Talk, incl. two PGN632=11.31 test data graphs: http://tinyurl.com/7w4udz.
......SK: "This data opens the door to a # of potential commercial app's incl. post-exposure prophylaxis & topical microbicides” http://tinyurl.com/cxv2st
.....1-24-09: Mojo’s Comparison Graphs of Bavi vs. 11.31(PGN632) against HIV (in-vitro): http://tinyurl.com/dkmrdp
.....1-6-09: NIAID reviews CapeTown AIDS’08, commenting on the Tony Moody Anti-Lipids/PGN632 talk: http://tinyurl.com/7dnmpe
.....1-15-09: JBM’s 'AIDS-Vaccine’08/Capetown Wrapup' (Anti-PS Blog): http://tinyurl.com/8cmmcs
.....2-23-09 Duke article about 2F5, a ‘Rare, Potent Antibody to HIV-1’ – comp. vs. PGN632: http://tinyurl.com/aozpd2
…9-22-08: Haynes CAVD Update: ”The team has recently found that non-pathogenic anti-lipid antibodies that do not require B2GPI for lipid binding do prevent HIV-1 & SHIV-SF162P3 (and all R5 HIVs tested) from infecting PBMC in vitro..." http://tinyurl.com/3g6vbm
…12-2007: UCLA’s Dr. Pojen Chen (active in CHAVI/Duke HIV studies) joins PPHM’s SRB: http://tinyurl.com/2nxcm2
...7-2007: PPHM licenses "certain Anti-PS Antibodies" from UCLA - the Dr. Pojen Chen connection? http://tinyurl.com/5t8jvm
…4-24-07: GATES-FOUND. rep's lecture at U-WASH lists P.Thorpe on CAVD grants map: http://tinyurl.com/3t67gj
...3-2007: Duke’s D.Montefiori Europrise-HIV Assay paper refs. “BAVITUX” & “3G4RHD” http://tinyurl.com/448d8k
…1-27-07: Dr. Haynes (Chavi Dir.) report - pg.31 shows slide “Labeling of Microparticles by Anti-PS Antibodies”: http://tinyurl.com/289a5g
...JBM’s educational blog on Anti-PS science, esp. HIV: http://anti-ps.blogspot.com
...Haynes-BF pubs: http://tinyurl.com/3nspyw ...Moody-MA pubs: http://tinyurl.com/5yeh2e
...Duke Health News: http://www.dukehealth.org/HealthLibrary/News ...CAVD(Gates) Annual repts: http://tinyurl.com/47uhtu
BAVITUXIMAB ANTI-CANCER NEWS:
1-13-10: Peregrine’s Ambitious Goal for Bavi: Accelerated Approval after Phase II: http://tinyurl.com/y9gsf9x
11-10-09: Thorpe CCR(AACR) article on Bavi+RAD vs. GBM http://tinyurl.com/y8kdz2m
…Dr.Thorpe, “…[Bavi] may also prove to be an effective new agent against glioblastoma."
8-31-09: Noted Oncologist Dr. Bruce Chabner [ClinDir/MassGH] joins as Advisor http://tinyurl.com/lma24x
…”Dr. Chabner will serve as a clinical advisor to the company on the design of clinical trials for the Bavi cancer pgm.”
6-24-09 U.S. Patent #7,550,141 granted: Anti-PS for Tumor Imaging: http://tinyurl.com/ln9ub8
6-10-09: ASCO $200k Grant to UTSW's David Gerber for New Bavi/NSCLC Study: http://tinyurl.com/nt4na9
6-1-09 ASCO’09: Ph.2 Bavi+Doce/MBC/GA, Oral Presentation: http://tinyurl.com/pbf9gw
6-1-09 ASCO’09: Ph.1 Bavi-Mono/Solid-Tumors/USA, Poster: http://tinyurl.com/p7jku7
4-22-09 AACR2009 #5463: Fully-Human Anti-PS (PGN635=1N11) ‘Inhibits the Growth of Prostate Cancer in Mice by 90%’ http://tinyurl.com/cparur
4-21-09 AACR2009 #2408+2407: Anti-PS Immunomodulatory Mechanisms (PGN632/635) http://tinyurl.com/c83p8b
…Dr. Phillip Thorpe: "These presentations provide addl. insight into the mechanisms that act to selectively destroy the blood vessels supporting tumor growth & spread and also to reverse the ability of tumors to suppress the body's natural immune response, resulting in the mobilization of important inflammatory and other anti-tumor components of the immune system. Together, they provide compelling evidence suggesting that PS-targeting antibodies facilitate an important cytokine shift in the tumor environment that subsequently encourages multiple types of immune system cells to mount anti-tumor responses."
~7-2008: UTSW Article profiles Drs. P.Thorpe & R.Brekken Research (PPHM SRB): http://tinyurl.com/cmzgkd
PRIMA-1 + 2aG4 Combo Studies, Thorpe & Univ.Missouri:
…6-18-08: U-Missouri Article on Thorpe Collab. w/Dr. Hyder: http://tinyurl.com/4al5bp
.....Dr Hyder, "The results of this study are very promising and show the possibility of broad anti-cancer potential."
…4-14-08: AACR2008 #2341, PRIMA-1+2aG4 (Dr. S.Hyder, U-Missouri) http://tinyurl.com/6487bs
…...Dr. Liang: "PRIMA-1+2aG4 combo therapy has a complementary & potent anti-tumor activity and could define a new strategy for suppression of advanced breast cancers."
4-15-08: AACR2008 #4079, Bavi/PGN635(fully-human) Induces ADCC http://tinyurl.com/6ql5nf
…S.King,”by blocking PS and its anti-inflammatory signals, our anti-PS antibodies unleash powerful pro-inflammatory effects that enhance their anti-cancer effectiveness.”
...5-6-08 Affitech's followup PR on PGN635: http://tinyurl.com/3h26wk
...10-23-08 Affitech presents 1N11/PGN635(Bavi) & R84/PGN311(2C3) at ANTIBODIES-EUR: http://tinyurl.com/4w9qba
4-15-08: AACR2008 #2841, Anti-PS Immunocytokines http://tinyurl.com/4bz8ym
...”80% of mice rec. prophylactic pre-treatment [2aG4:IL2] with irradiated breast cancer & immunocytokine cells did not develop any tumors and remained tumor-free after 270 days.”
4-15-08: AACR2008 #2551, Bavi+Docetaxel/Prostate http://tinyurl.com/5oaejo
...”2aG4+Doce reduced primary tumor burden by 95%”. S.King, ”the combo of a Bavi(equiv.)+Doce eliminated the production of detectable metastases entirely...”
4-11-08 AACR2008: PR for 4 PPHM Presentations (5 Abstracts found): http://tinyurl.com/aarjwg
3-3-08: Thorpe/Mason C.C.R. (AACR) article on Arsenic-labeled Bavi for Imaging Tumors: http://tinyurl.com/32jbfl
BAVITUXIMAB ANTI-CANCER NEWS - Archive 2005-2007: http://tinyurl.com/yanupve
TUMOR NECROSIS THERAPY (TNT/COTARA/VEA’s) NEWS:
1-19-10: PPHM & Stason websites show non-binding agreement to dev. TNT in Asia http://tinyurl.com/ybl92b7
…”Peregrine & Stason Pharm. have entered into a non-binding agreement to pursue a collaboration for developing TNT technologies in certain Asia-Pacific countries. The proposed collaboration would allow Peregrine to establish a regional partner for its proprietary TNT technology platform with an established pharmaceutical company that possesses expertise & experience in developing & marketing cancer therapies throughout the Asia-Pacific region.”
7-1-09 Eur. Patent #1638989 for ‘In-Line Labeling’ (used in Cotara GBM trials) & JNM Article: http://tinyurl.com/mlgz8p
India Cotara/Brain Ph.2 Trial (40 patients, 1st relapse):
India’s DCGI protocol (init=7-2007): http://clinicaltrials.gov/ct2/show/NCT00677716
…9-2-09 Interim Ph.2 data (10 pts) presented at AANS Annual Mtg/Boston: http://tinyurl.com/mxzbzm
……P.I. Dr. A.K. Mahapatra: “Most importantly, Cotara has demonstrated promising signs of efficacy.”
...8-2-07 1st Patient Dosed in Indian Cotara/Brain Ph.2 Trial: http://tinyurl.com/296mcj
...The obvious desire is to compare Cotara vs. SOC Temodar for GBM therapy: http://tinyurl.com/yttt99
USA Cotara/Brain ‘Dosimetry & Dose Confirmation Trial’ (originally funded by NABTT):
U.S.A. Cotara Brain Cancer trial protocol (added 8-14-07): http://clinicaltrials.gov/show/NCT00509301
...12-2-09: U.S. Trial Enrollment Complete http://tinyurl.com/yez7lzd
...6-16-09: Cotara/Brain Oral-Pres. at SNM Annual Meeting http://tinyurl.com/lmhkw2
......Dr. Sui Shen (U-Alabama), “With a mean dose ratio showing 300-fold greater delivery of radiation to the tumor as compared to other organs, Cotara represents a potentially valuable new therapy for GBM patients."
…9-23-08: Article in Cleveland paper – comments by P.I. Dr. Andrew Sloan (Case Western/CLEV) http://tinyurl.com/3mkmas
...5-31-08: Cotara USA Ph.1B data presented at ASCO/2008: http://tinyurl.com/68apro
...8-29-05: NABTT Initiates Cotara/Brain Trial (28 patients/4 sites): http://tinyurl.com/9w3cr
...Orig. NABTT protocol, “6-2007, completed”: http://www.clinicaltrials.gov/ct/show/NCT00128635
...The Phil (Marfuta) Bannister Story (NABTT Cotara/GBM patient #1, diag. 2-4-06) - articles & updates: http://tinyurl.com/24gkml
.....Update 12-29-08: Phil posts on iHub that he's doing OK (34 mos. since diag.): http://tinyurl.com/8r5fnz
.....Update 10-14-09: Phil posts on YASG.com that he’s doing well, 44 mos. after diagnosis: http://tinyurl.com/yfbpk57 Previous USA Cotara/Brain Ph.1-2 Trials, completed in 2003:
...Slides showing correlation between Cotara dosage levels and MST vs. Temodar(curr.SOC): http://tinyurl.com/26s265
...4-27-08 update: The Jerod Swan Cotara/Brain Success Story (10 years after diag.): http://tinyurl.com/68ofsv
...5-22-07 update: The Freddie Sanford Cotara/Brain Success Story (7 years after diag.): http://tinyurl.com/2du2e5
...6-1-05: Cotara w/CED Brain Delivery pub. in Neurosurgery Jrnl: http://tinyurl.com/anmaa
...”Cotara Holds Promise for Treating Brain Cancer - P1/P2 Data Suggests Extended Survival in a Number of Patients"
TNT3 (Vivatuxin) Lung Cancer Approval/Launch in China:
...Shanghai MediPharm Biotech’s TNT/China website: http://www.vivatuxin.com
...1-16-07: Medipharm Launches TNT in China for Lung Cancer http://tinyurl.com/ttlne
...6-19-02: TNT Interim Lung Data from China: http://tinyurl.com/ggcba & http://tinyurl.com/em6da
Peregrine v. CTL Lawsuit – Settled 6-19-09:
...6-19-09: Form 8-K, Peregrine & CTL Settle: http://tinyurl.com/mhgcg7
...3-29-07 CTL countersues PPHM over TNT/China licensing dispute: http://tinyurl.com/39k8sx
...3-30-07 PPHM comments on CTL's 3-29-07 countersuit: http://tinyurl.com/33xzzq
...1-12-07: New China Subsidiary; Suit Filed Against Cancer Therapeutics Labs (CTL) http://tinyurl.com/y4vzbj
Eur. Licensee Merck-KGaA’s TNT/Cytokine Fusion Protein Ph.1 Trial:
...4-2009: 2nd SELECTIKINE Ph.1 trial added: SELECTIKINE+RAD/NSCLC: http://tinyurl.com/pzl9j8
...5-2007: 2nd SELECTIKINE Ph.1 site added, Univ. of Lausanne, Switz: http://tinyurl.com/2l933s
...Ph.1 Trial Protocol (Merck KGaA/Germany, PI=Dr. R.Stupp): http://tinyurl.com/2f4u2t
...2-22-07: TNT-based European Cancer Trial initiated by ‘Licensee’: http://tinyurl.com/2zcjqr
...Clearly, it's Merck-KGaA's 'SELECTIKINE' (NHS-IL2-LT/EMD521873): http://tinyurl.com/yud7pw
VEAs:
...5-1-08 Dr. Missag Parseghian (Dir/R&D) presents VEAs at PEGS/2008: http://tinyurl.com/66onj2
...NOTE: Drs. Parseghian (Dir.R&D) & Luhrs, key PPHM TNT/VEA researchers: http://tinyurl.com/2ahhdp
ANTI-ANGIOGENESIS AGENT ’2C3’ (ANTI-VEGF MAB):
11-3-09/PLoS: R.Brekken (PPHM SRB) on R84, increases “immune cell infiltration” in Breast Cancer: http://tinyurl.com/y8ooxah
7-22-09: Peregrine Licenses Anti-VEGF mabs (incl. R84) to Affitech: http://tinyurl.com/n67v57
6-30-09: R.Brekken article in Mol-Cancer-Ther on 2C3/R84+Avastin vs. Breast Cancer: http://tinyurl.com/mqv5ol
12-11-08: Dr. Brekken (PPHM SRB) presents F.H. 2C3 (R84/PGN311) at TX Breast-Cancer Conf. http://tinyurl.com/63utya
11-3-07: Dr. Brekken presents ‘R84’ (F.H. 2C3, aka PGN311) data at IBC-Conf: http://tinyurl.com/yp459d
4-16-07 AACR2007: Brekken [PPHM SRB] presents fully-human 2C3 (‘R3’) http://tinyurl.com/2udkgr
”The anti-tumor activity of 2C3, which only blocks VEGFR2 compared favorably to that of Avastin, which blocks both VEGFR1+2”
2-14-05: Humanized 2C3 Pre-Clin. data presented at "Anti-Angio. Symposium": http://tinyurl.com/85qy3
2-10-05: VEGF Pioneer Dr. Donald Senger joins PPHM’s SRB to assist with 2C3 pgm: http://tinyurl.com/yul72w
5-20-03: PPHM compares 2C3 vs. Genentech’s AVASTIN: http://tinyurl.com/37k2nl
OTHER PEREGRINE DRUG CANDIDATES:
1-9-07 PR: VTA Microbubbles as Contrast Agents (AACR/CCR article) http://tinyurl.com/v7mf9 & http://tinyurl.com/w4pe9
9-26-06: VTA+Combo Patent Granted; Expands VTA Licensing Opportunities http://tinyurl.com/er4hh & http://tinyurl.com/ry5a4
8-25-05: PPHM Licenses Conjugated Anti-PSMA VTA Technolody to Medarex: http://tinyurl.com/dv6rt
"These types of deals should add considerable value to the company as our partners move their VTA dev. programs forward."
4-19-05: VEGF121/rGel presented at AACR (50% Survival vs. Prostate Cancer): http://tinyurl.com/8gazv
###SUPG moving VEGF121/rGel (lic. from PPHM) fwd. via Targa/Rosenblum: http://tinyurl.com/ylevod
...Rosenblum 11-15-06, "Ph.I human trials of VEGF121/rGel are expected to open shortly at M. D.A."
BACKGROUND ON 3G4/BAVITUXIMAB(formerly Tarvacin):
Thorpe 10-25-04 SHM Presentation: “Understanding Tarvacin”, incl. his first-ever public comments about Tarvacin's ANTI-VIRAL capabilities:
”OK, this is Tarvacin.. the cleanest tumor vessel marker of which we are aware.. If you look here at the 3G4 slide, you'll see, most remarkably, that it's absolutely chock full with macrophages; they're beginning to outnumber the tumor cells... . So, the conclusions with Tarvacin are that it has a unique mechanism of action, there's nothing else like it out there; it homes specifically to tumor blood vessels and induces white blood cells to attack the tumor.”
http://tinyurl.com/38qjug
Dr. Thorpe’s APT (AntiPS/3G4/BAVITUXIMAB patent app #20040161429 (pub. USPO 8-19-04):
“Compositions for treating Viral Infections using Immunoconjugates to Aminophospholipids”: http://tinyurl.com/6pdny
[1302] “the 3G4 antibody has enormous potential as a broad spectrum anti-viral agent.”
[1303] “...The inhibitory activities of 3G4 on cell division, angiogenesis, tumor growth & viral infectivity, taken together with lack of apparent toxicity, show broad therapeutic indications for this antibody, including in the treatment of angiogenic disorders, cancer, diabetes and viral infections.”
[0196] “the anti-viral methods and uses of the invention are suitable for treating all viruses... as exemplified by treating CMV, RSV, arenavirus and HIV infections, and the diseases hepatitis, influenza, pneumonia, Lassa fever and AIDS.”
[1298] “The 3G4 antibody has also been administered to monkeys in safety studies and no side effects have been observed.”
Thorpe’s Aug03-Jan08 $1.68mm NIH/NIAID Grant for research using PPHM’s APTs (Anti-PS/3G4) as “Novel Anti-Viral Agents for Treating Lassa Fever”:
Thorpe: “We are developing drugs to use against Lassa fever that operate on a new principle in virology. They exploit the fact that viruses coat themselves with an outer membrane where some of the lipids are inside-out. The drugs direct our immune responses to the inside-out components of the viral membrane, or envelope. These drugs potentially could be effective against numerous viruses that have similar outer membranes… We have raised mabs to PS and other anionic phospholipids that block the spread of several viruses to uninfected cells in vitro, essentially completely. The phospholipids that they recognize have the same structure & cellular distribution in different mammalian species, simplifying the transition from experimental animals into humans. The antibodies are not toxic to mice, even when administered in high doses for prolonged periods of time.”
GRANT LINK: http://tinyurl.com/5ntcm . . .11-3-03 Grant PR: http://tinyurl.com/5aulds
###8-26-09: $763k expansion NIAID grant to Dr. Thorpe for 2nd-gen. anti-PS/VHF studies: http://tinyurl.com/lxtuo3
The Inventor of the Anti-PS mab ‘3G4/bavituximab’ is Dr. Philip E. Thorpe of UTSW-MC/Dallas.
BIO: http://www.utsouthwestern.edu/findfac/research/0,2357,17308,00.html ...Thorpe's LAB TEAM: http://tinyurl.com/yuxemu
DR. THORPE'S PATENTS: GRANTED: http://tinyurl.com/m232k PENDING: http://tinyurl.com/845p2
DR. THORPE'S ARTICLES: http://tinyurl.com/csjsl
PPHM BOARD RULES: http://tinyurl.com/zx2qa
DISCLAIMER: This msg board is not affiliated with Peregrine; no endorsement by Peregrine or any other org. is implied.